Posts Tagged: michael carrier


The Fifth Circuit Must Preserve the Patent-Antitrust Balance by Upholding Actavis

The pharmaceutical industry presents some of the most important and challenging issues lying at the intersection of the patent and antitrust laws. On the one hand, patents …
By Michael Carrier
6 months ago 0

The Supreme Court’s Actavis Decision, Or Why Pay-for-Delay Litigation Just Got More Active

In this case, the Supreme Court considered an arrangement by which brand firm Solvay paid generics Watson (now Actavis) and Paddock roughly $30 to $40 million to delay entering …
By Michael Carrier
7 years ago 1

Supreme Court Agrees To Tackle Drug Patent Settlements

In the past several years, the Second, Eleventh, and Federal Circuits have upheld these settlements (known as “reverse payment” agreements since the money flows from the patentee …
By Michael Carrier
7 years ago 4

Reverse Payment Home Run for Pharma Antitrust Enforcement

One of the most complex issues in antitrust and patent law today involves agreements by which brand-name drug companies pay generics to delay entering the market. In …
By Michael Carrier
8 years ago 9

A Special Thank You to Our Guest Contributors!

Over the years IPWatchdog.com has continued to try and add additional perspectives from a wide variety of guest contributors, ranging from well respected practicing attorneys and …
By Gene Quinn
9 years ago 3

An Inconvenient Truth: Patents Do Not Deter Research

Carrier goes on to detail the comprehensive research of Professor John Walsh who in 2007 surveyed 1125 biomedical researchers in universities, government labs and nonprofit institutions. Walsh received 414 responses …
By Gene Quinn
9 years ago 22

Hatch-Waxman at the Supreme Court: Supporting Cert. in Cipro

One of the most debated issues in patent and antitrust law today involves pharmaceutical patent settlements. Brand-name drug manufacturers pay generic firms to settle patent litigation and …
By Michael Carrier
9 years ago 1